Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.

Maddur MS, Stephen-Victor E, Das M, Prakhar P, Sharma VK, Singh V, Rabin M, Trinath J, Balaji KN, Bolgert F, Vallat JM, Magy L, Kaveri SV, Bayry J.

J Neuroinflammation. 2017 Mar 20;14(1):58. doi: 10.1186/s12974-017-0818-5.

2.

Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.

Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC.

JAMA Neurol. 2017 Feb 1;74(2):189-196. doi: 10.1001/jamaneurol.2016.4480.

PMID:
28027337
3.

Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, Magy L, Bayry J, Kaveri SV.

Immunol Res. 2014 Dec;60(2-3):320-9. doi: 10.1007/s12026-014-8580-6.

4.

Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome.

Mori I, Parizot C, Dorgham K, Demeret S, Amoura Z, Bolgert F, Gorochov G.

PLoS One. 2008 May 7;3(5):e2109. doi: 10.1371/journal.pone.0002109.

5.

Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury.

Zhang G, Massaad CA, Gao T, Pillai L, Bogdanova N, Ghauri S, Sheikh KA.

Exp Neurol. 2016 Aug;282:49-55. doi: 10.1016/j.expneurol.2016.05.020. Epub 2016 May 18.

6.

Intravenous immunoglobulin G modulates peripheral blood Th17 and Foxp3(+) regulatory T cells in pregnant women with recurrent pregnancy loss.

Kim DJ, Lee SK, Kim JY, Na BJ, Hur SE, Lee M, Kwak-Kim J.

Am J Reprod Immunol. 2014 May;71(5):441-50. doi: 10.1111/aji.12208. Epub 2014 Mar 19.

PMID:
24645850
7.

IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.

Fokkink WJ, Selman MH, Dortland JR, Durmuş B, Kuitwaard K, Huizinga R, van Rijs W, Tio-Gillen AP, van Doorn PA, Deelder AM, Wuhrer M, Jacobs BC.

J Proteome Res. 2014 Mar 7;13(3):1722-30. doi: 10.1021/pr401213z. Epub 2014 Feb 17.

PMID:
24533874
8.

Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.

Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, Magy L, Balaji KN, Kaveri SV, Bayry J.

Blood. 2013 Aug 22;122(8):1419-27. doi: 10.1182/blood-2012-11-468264. Epub 2013 Jul 11.

PMID:
23847198
9.

Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome.

Chi LJ, Wang HB, Zhang Y, Wang WZ.

J Neuroimmunol. 2007 Dec;192(1-2):206-14. Epub 2007 Nov 13.

PMID:
17997492
10.

Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome.

Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD.

Indian J Med Res. 2003 May;117:216-20.

PMID:
14609050
11.

Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease.

Hirabayashi Y, Takahashi Y, Xu Y, Akane K, Villalobos IB, Okuno Y, Hasegawa S, Muramatsu H, Hama A, Kato T, Kojima S.

Eur J Pediatr. 2013 Jun;172(6):833-7. doi: 10.1007/s00431-013-1937-3. Epub 2013 Jan 23.

PMID:
23340699
12.

Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments.

Li S, Jin T, Zhang HL, Yu H, Meng F, Concha Quezada H, Zhu J.

Mediators Inflamm. 2014;2014:740947. doi: 10.1155/2014/740947. Epub 2014 May 12.

13.

Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome.

Li C, Zhao P, Sun X, Che Y, Jiang Y.

Mediators Inflamm. 2013;2013:639712. doi: 10.1155/2013/639712. Epub 2013 Sep 19.

14.

Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner.

Lee SY, Jung YO, Ryu JG, Kang CM, Kim EK, Son HJ, Yang EJ, Ju JH, Kang YS, Park SH, Kim HY, Cho ML.

Arthritis Rheumatol. 2014 Jul;66(7):1768-78. doi: 10.1002/art.38627.

15.

Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment.

Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, Aghebati-Maleki L, Dolati S, Farzadi L, Ghasemzadeh A, Hamdi K, Younesi V, Nouri M, Yousefi M.

Syst Biol Reprod Med. 2017 Dec;63(6):350-359. doi: 10.1080/19396368.2017.1390007. Epub 2017 Nov 3.

PMID:
29099629
16.

Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.

Reuben S, Sumi MG, Mathai A, Nair MD, Radhakrishnan VV.

Neurol India. 2003 Dec;51(4):487-9.

17.

Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin.

Hou HQ, Miao J, Feng XD, Han M, Song XJ, Guo L.

BMC Neurol. 2014 Oct 15;14:202. doi: 10.1186/s12883-014-0202-3.

18.

Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.

Guo MM, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC.

Allergy. 2015 Mar;70(3):310-8. doi: 10.1111/all.12558. Epub 2015 Jan 14.

PMID:
25585854
19.

Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis.

Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N.

Blood. 2008 Jan 15;111(2):715-22. Epub 2007 Oct 11.

PMID:
17932250
20.

Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome.

Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD.

Acta Neurol Scand. 2004 Jan;109(1):71-4.

PMID:
14653854

Supplemental Content

Support Center